We sort to validate the proteomic prognostic biomarkers by examining ICAM-1, PMEL, and ITGAV mRNA transcript levels from 69 AJCC Stage III melanoma tissue specimens with either BRAF V600E/G/K/R or NRAS Q61H/K/R mutations that were submitted to TCGA and subsequently extracted from the NIH Genomic Data Commons database using the TCGA-SKCM EE cases identifier (https://portal.gdc.cancer.gov/projects/TCGA-SKCM). Here, ITGAV is linked to melanoma.